MGNX currently has a WACC of 9.08%. However, its ROIC is -49.59%. This means the company is not yet generating a profit on its investments. This situation is common for biopharmaceutical firms that are still in the clinical stage, investing heavily in research before their products are sold. MacroGenics, Inc. (NASDAQ: MGNX) is a biopharmaceutical company that develops antibody-based treatments for cancer. It operates in a competitive field alongside peers like Xencor, Inc. (NASDAQ: XNCR), Karyopharm Therape ...